Delving into the Latest Updates on Qingdao Primedicine Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Cardiovascular Diseases

Other Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	6
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	7
Synthetic peptide	2

Top 5 Target	Count

GluN2A x GluN2B	2
GluN2A(glutamate ionotropic receptor NMDA type subunit 2A)	1
NMDA receptor(Glutamate [NMDA] receptor)	1
AMPA receptor(Glutamate receptor ionotropic AMPA)	1
GlyR(Glycine receptor)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

6

Preclinical

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PMS-001 ( AMPA receptor )	Acute Ischemic Stroke More	Phase 1
Npam 43 ( GluN2A )	Stroke More	Preclinical
Npam105 ( GluN2A x GluN2B )	Alzheimer Disease More	Preclinical
Npam217 ( GluN2A x GluN2B )	Schizophrenia More	Preclinical
PMS-002 ( NMDA receptor )	Schizophrenia More	Preclinical